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CLINICAL HIGHLIGHTS
Infection with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), resulting in coronavirus disease 2019 (COVID-
19), can lead to acute respiratory distress syndrome, requiring
hospitalization and sometimes death in a subset of patients.
The elderly and immunosuppressed subjects are particularly
vulnerable to COVID-19, and these characteristics are often
present in cancer patients. It is therefore conceivable that
patients with cancer are at a greater risk of infection and may
present a more serious form of COVID-19 disease. The epide-
miological data, derived by case series and retrospective stud-
ies, do not offer a coherent interpretation regarding the in-
creased propensity of cancer patients to be diagnosed with
COVID-19, but suggest that these patients may have more
severe COVID-19 symptoms compared with the general popu-
lation. The data can be explained by the understanding of im-
munometabolic pathways that intersect patients with infection
and cancer. In particular, macrophages play a central role in
dysfunctions associated with cancer and COVID-19 infection.
Tumors induce an alternative macrophage activation state
(M2) that promotes immunosuppression and tumor progres-
sion. This situation coincides with decreased antiviral activity,
exposing it to an increased susceptibility to infections. Viral
infections (e.g., COVID-19) directly or indirectly
promote classical M1 type inflammatory activa-
tion, associated with macrophage-activating syn-
drome, lymphopenia, endothelial damage, and hy-
percoagulation. Although macrophages develop
opposite functional programs in the two patholo-
gies, in both cases they appear as the coordina-
tors of pathological changes, representing com-
mon therapeutic targets.
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COVID-19 Cancer Patients. Physiol Rev 100: 1839–1850, 2020. First published July 28, 2020;
doi:10.1152/physrev.00018.2020.—Cancer patients appear to be more likely to be diagnosed
with coronavirus disease 2019 (COVID-19). This is supported by the understanding of immuno-
metabolic pathways that intersect patients with infection and cancer. However, data derived by
case series and retrospective studies do not offer a coherent interpretation, since data from China
suggest an increased risk of COVID-19, while data from the United States and Italy show a
prevalence of COVID-19 in cancer patients comparable with the general population. Noteworthy,
cancer and COVID-19 exploit distinct patterns of macrophage activation that promote disease
progression in the most severe forms. In particular, the alternative activation of M2-polarized
macrophages plays a crucial role in cancer progression. In contrast, the macrophage-activation
syndrome appears as the source of M1-related cytokine storm in severe COVID-19 disease, thus
indicating macrophages as a source of distinct inflammatory states in the two diseases, nonethe-
less as a common therapeutic target. New evidence indicates that NAMPT/NAD metabolism can
direct both innate immune cell effector functions and the homeostatic robustness, in both cancer
and infection. Moreover, a bidirectional relationship exists between the metabolism of NAD and the
protective role that angiotensin converting enzyme 2, the COVID-19 receptor, can play against
hyperinflammation. Within this immunometabolic framework, the review considers possible inter-
ference mechanisms that viral infections and tumors elicit on therapies and provides an overview
for the management of patients with cancer affected by COVID-19, particularly for the balance of
risk and benefit when planning normally routine cancer treatments and follow-up appointments.
cancer; comorbidity; COVID-19; SARS-CoV-2
I. INTRODUCTION 1839
II. AGING, HOMEOSTATIC FRAGILITY,... 1843
III. GENDER AND VIRAL INFECTION 1843
IV. MECHANISMS OF VIRUS-INDUCED... 1843
V. ACE2 AND INFLAMMATION 1845
VI. MUTUAL INTERFERENCE OF... 1845
VII. CONCLUSION 1847
I. INTRODUCTION
In December 2019, a novel coronavirus named severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) caused
an outbreak of coronavirus disease 2019 (COVID-19) (10).
The rapid global spread led the World Health Organization
(WHO) to declare a pandemic in early March 2020 (WHO
Director-General’s opening remarks at the media briefing
on COVID-19, March 11, 2020: https://www.who.int/dg/
speeches/detail/who-director-general-s-opening-remarks-
at-the-media-briefing-on-covid-19---11-march-2020).
Initial reports suggested that patients with comorbidities
had a higher risk of mortality or developing more severe
forms of COVID-19. In particular, patients with cardiovas-
cular diseases, hypertension, cancer, and diabetes were
thought to be particularly at risk (5, 6) . Patients with cancer
are generally more susceptible to infection and therefore to
SARS-CoV-2 as well. A report of 1,524 cancer patients who
were screened at Zhongnan Hospital of Wuhan University
identified COVID-19 in 12 (0.79%) patients, 7 of whom
had non-small-cell lung cancer (NSCLC), leading the au-
thors to conclude that patients with cancer had a higher risk
of infection with SARS-CoV-2 compared with the commu-
nity (12). Other data reported the prevalence of cancer
among COVID-19 patients with a range varying from 1 to
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6% in Asian populations (20a) and as high as 18% in west-
ern countries (5a, 31, 68). In all these studies, hypertension,
diabetes, and cardiovascular and chronic obstructive pul-
monary diseases were much more common than cancer.
However, these analyses were limited by the sample size and
inherent bias in symptomatic patients being screened (32)
(TABLE 1).
Results from China, although limited in sample size,
showed that patients with cancer deteriorated more rapidly
than those without cancer and were at higher risk of severe
complications from COVID-19 including death (17). Re-
cent data from the English collaboration OPENSafely
(~6,000 deaths from COVID-19; Ref. 78a) support previ-
ous evidence showing a three times higher risk of death in
patients diagnosed with a hematological malignancy up to 5
yr before SARS-CoV-2 infection. The excess risk of death
seemed to be lower for other cancer types than that of
hematological tumors but was also significant (hazard
ratio 1.56), especially for subjects diagnosed with cancer
within 1 yr of SARS-CoV-2 infection (78a). These results
were confirmed by other multicenter and single center
studies (17, 36).
However, these publications are limited as the majority de-
scribed hospitalized patients and the inherent bias that can-
cer patients could more likely be tested for SARS-CoV-2
because of their symptoms and of the frequent access to the
health care facilities (14, 15). Data from outpatients with
mild symptoms or from suspected patients under home ob-
servation and awaiting a diagnosis are currently lacking.
Thus to what extent cancer patients are vulnerable to
COVID-19 and whether frailty may be driven by age, gen-
der, and other comorbidities often present in cancer pa-
tients are still a matter of debate. A further question arises
on variability of prognosis of COVID-19 cancer patients
across cancer types. Cancer-specific data coming from can-
cer patient registries established recently (TERAVOLT;
Ref. 86), a global consortium specifically created to address
the impact of COVID-19 in patients with thoracic malignan-
cies (NSCLC, small cell lung cancer, malignant pleural meso-
thelioma, thymic malignancies, and neuroendocrine tumors),
provide some preliminary indication. TERAVOLT results
from 200 patients showed that ~33% patients died. Impor-
tantly, 74% of these patients were on active treatment, and
54% of them were on a first line (38a, 86). In addition,
TERAVOLT results suggested an increased risk of death in
patients treated with steroids or anticoagulation before di-
agnosis and showed that chemotherapy, alone or in combi-
nation with immunotherapy, was associated with increased
risk of death, while immunotherapy and tyrosine kinase
inhibitors were not. The high COVID-19-related mortality
in thoracic cancer patients is indirectly confirmed by further
data; in ASCO 2020, results from CCCN-19 were also pre-
sented on 926 cancer patients (45). Mortality in this pan-
cancer population was 13%, with ECOG-PS at diagnosis,
sex, older age, and smoking associated with the increased
risk of death.
Another observational registry enrolled 800 patients with
active cancer into the United Kingdom Coronavirus Cancer
Monitoring Project (UKCCMP): 412 (52%) patients had a
mild COVID-19 disease course, 226 (28%) patients died,
and risk of death was significantly associated with advanc-
ing patient age [odds ratio 9.42; 95% confidence interval
(CI) 6.56–10.02; P  0.0001], being male (odds ratio 1.67;
95% CI 1.19–2.34; P  0.003), and the presence of other
comorbidities such as hypertension (odds ratio 1.95; 95%
CI 1.36–2.80; P  0.001) and cardiovascular disease (odds
ratio 2.32; 95% CI 1.47–3.64).
The authors found no significant effect on mortality for
patients with chemotherapy, immunotherapy, hormonal
therapy, targeted therapy, or radiotherapy use within 4 wk.
Data from 205 patients from 9 hospitals in Hubei, China,
were enrolled in a retrospective study (88); 183 (89%) had
solid tumors, and 22 (11%) had hematological malignan-
cies. Clinical characteristics, laboratory data, and cancer
histories were compared between survivors and non-survi-
vors. Results showed that patients with cancer and
COVID-19 who were admitted to the hospital had a high
case-fatality rate, and chemotherapy within 4 wk before
symptom onset and male sex were associated with high risk
of fatal outcomes (47).
Infection with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), resulting in coronavirus disease 2019 (COVID-
19), can lead to acute respiratory distress syndrome, requiring
hospitalization and sometimes death in a subset of patients.
The elderly and immunosuppressed subjects are particularly
vulnerable to COVID-19, and these characteristics are often
present in cancer patients. It is therefore conceivable that
patients with cancer are at a greater risk of infection and may
present a more serious form of COVID-19 disease. The epide-
miological data, derived by case series and retrospective stud-
ies, do not offer a coherent interpretation regarding the in-
creased propensity of cancer patients to be diagnosed with
COVID-19, but suggest that these patients may have more
severe COVID-19 symptoms compared with the general popu-
lation. The data can be explained by the understanding of im-
munometabolic pathways that intersect patients with infection
and cancer. In particular, macrophages play a central role in
dysfunctions associated with cancer and COVID-19 infection.
Tumors induce an alternative macrophage activation state
(M2) that promotes immunosuppression and tumor progres-
sion. This situation coincides with decreased antiviral activity,
exposing it to an increased susceptibility to infections. Viral
infections (e.g., COVID-19) directly or indirectly promote classi-
cal M1 type inflammatory activation, associated with macro-
phage-activating syndrome, lymphopenia, endothelial damage,
and hypercoagulation. Although macrophages develop opposite
functional programs in the two pathologies, in both cases they
appear as the coordinators of pathological changes, represent-
ing common therapeutic targets.
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All these epidemiological results, although still preliminary,
are the starting point to deepen the immune pathogenesis
and pathophysiological characteristics of prognostic factors
potentially contributing to the vulnerability to SARS-
CoV-2 of cancer patients.
II. AGING, HOMEOSTATIC FRAGILITY, AND
VIRAL INFECTION
Pathophysiological changes and metabolic complications,
which establish a subclinical syndrome of “homeostatic
frailty,” are common among the elderly population and are
associated with greater susceptibility to infection (75).
These changes determine immune-senescence and an imbal-
ance between inflammatory and anti-inflammatory mecha-
nisms (23) [e.g., high levels of inflammatory mediators such
as interleukin (IL)-6, tumor necrosis factor-, and C-reac-
tive protein]. Consistent with these data in elderly sub-
jects, failure to resolve the inflammatory process often
occurs, undermining both the metabolic and immune
pathways (75).
The system composed by the intracellular adipokine visfa-
tin (iNAMPT) and the NAD-dependent protein deacetylase
SIRT1 plays a key role in both maintaining a precise ener-
getic metabolism and enhancing the robustness of physio-
logical processes (13). Noteworthy, prior evidence shows
an age-related loss of iNAMPT/NAD/SIRT1 activity,
which undermines antioxidant, metabolic, and anti-inflam-
matory systems (28, 75). Furthermore, iNAMPT guides dif-
ferentiation of anti-inflammatory myeloid cells under stress
conditions (80). Of interest, fluctuation in NAD bioavail-
ability has been described during host-pathogen interac-
tions, which interfere with pathogen persistence or clear-
ance. Among these, human immunodeficiency virus, hepa-
titis virus B and C, influenza virus, Kaposi’s sarcoma virus,
and herpes virus were found to alter intracellular NAD
levels, either in innate or adaptive immune cells (55).
Overwhelming inflammation, consequent to loss of homeo-
static robustness at the onset of COVID-19-induced pneu-
monia, was observed, and the anti-IL-6 monoclonal anti-
body tocilizumab has been shown to negate aberrant lung
inflammation in some patients (51). Thus the sudden wors-
ening of clinical conditions observed in COVID-19 patients
appears in line with a virus-mediated breakout of physio-
logical mechanisms of robustness, which becomes a dra-
matic event in the elderly with comorbidities including can-
cer.
III. GENDER AND VIRAL INFECTION
It has been proposed that hypovitaminosis (i.e., vitamin D
deficiency) may contribute to viral disease development
(78). Interestingly, the robustness of the NAMPT/NAD/
SIRT1 system is controlled by a balanced nutritional supply
of tryptophan and vitamin B3, which provide the primary
and the rescue pathways for the synthesis of NAD, respec-
tively (5). Moreover, vitamin D increases NAD concentra-
tions and SIRT1 activity (8). The greater female resilience to
infections (42) and their higher risk for autoimmunity ap-
pear estrogen-linked (54). In this contest, frequent defi-
ciency of the estrogen-inducible vitamin D receptor was
found in COVID-19-positive patients (49). The alleged in-
terplay between estrogen and physiological robustness sys-
tems (NAMPT/NAD/SIRT1), together with the localiza-
tion of the coding gene angiotensin converting enzyme 2
(ACE2) on the X chromosome (X-linked) (93), provides a
possible rationale for higher female resilience to COVID-19
infection. On the other hand, males might be more suscep-
tible and prone to poor outcomes in relation to the andro-
gen receptor AR (57, 76). SARS-CoV-2 cell entry through
the ACE2 receptor requires the shortage of the virus spike
(S) protein by the cellular serine protease TMPRSS2 (38),
which is androgen regulated (85). In addition, single nucle-
otide polymorphism within an androgen-responsive ele-
ment could impact on TMPRSS2 expression (15), whereas
no clear genetic variants in the ACE2 gene have been asso-
ciated with virus entry to date (7).
IV. MECHANISMS OF VIRUS-INDUCED
IMMUNE AND METABOLIC
DYSREGULATIONS
In stress/pathological conditions (e.g., infection and can-
cer), signals derived from the hematopoietic stem cell niche
modify the magnitude and composition of hematopoietic
output, a feature of immune regulation defined as “emer-
gency” hematopoiesis, to guarantee an adequate supply of
both lymphoid and myeloid cells with increased demand
(61, 73). These alterations profoundly affect innate and
adaptive immune response, as well as disease outcome. Fur-
thermore, microenvironmental signals locally refine the ac-
tivation state of immune cells, acting through specific recep-
tors and leveraging their functional plasticity (74).
Airway macrophages (AMs) detect airborne pathogens,
including viruses, through surface and endosomal patho-
gen-recognition receptors (PRRs), whose engagement trig-
gers an antiviral interferon (IFN)-mediated response (10).
Highly pathogenic human coronaviruses such as severe
acute respiratory syndrome coronavirus (SARS-CoV) and
Middle East respiratory syndrome coronavirus (MERS-
CoV) were reported to predominantly infect lower airways
and cause fatal pneumonia (37, 46). Of relevance, in SARS-
CoV infection, CCL2 is a major chemoattractant for patho-
genic inflammatory monocytes, which produce monocyte
chemokines, hence enhancing disease severity (9). In
MERS-CoV patients, the severity of lung lesions has been
shown to correlate with extensive infiltration of neutrophils
and macrophages within the lungs and in peripheral blood
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(60). In support of a central role of NAD metabolism in
myeloid cells, the IFN-induced antiviral cascade operated
by macrophages utilizes the metabolic regulators NAMPT
and Sirt6 serially (18). In addition, extracellular (e)NAMPT
can behave as alarmin or damage-associated molecular pat-
tern (DAMP) and has been found to be elevated in patients
with comorbidities including diabetes, obesity, and cancer
(3) that worsen patient frailties to SARS-CoV-2, while it
marks sepsis and septic shock. Nevertheless, eNAMPT
promotes macrophage survival via the IL-6/STAT-3
pathways (48).
In COVID-19 patients, characterization of peripheral lym-
phocyte subsets showed a decreased frequency of CD4 T
cells, CD8 T cells, B cells, and natural killer cells, whereas
neutrophil count remains unchanged or elevated. Given the
diffuse evidence of vasculitis and coagulopathies, together
with recent description of associated antiphospholipid an-
tibodies (92), a role for neutrophils is foreseen. Indeed, sera
and plasma of patients with antiphospholipid syndrome
have elevated levels of both cell-free DNA and neutrophil
extracellular traps (NETs) (87). Of relevance, the NAD/
SIRT1 system also guarantees the production of hydrogen
sulfide (H2S), which acts as an endothelial signaling net-
work that ensures vascular wellness (19). According to this
scenario, the possible direct viral infection of endothelial
cells should be taken into account, since these cells express
the COVID-19 receptor ACE2 (22). This hypothesis ap-
pears substantiated by the lymphocytic endothelitis devel-
oping in the lung, heart, kidney, small intestine, and liver of
COVID-19 patients (81). As such, integrity of NAD-depen-
dent system in endothelial cells may be relevant, since its
intracellular activity ensures vascular repair after isch-
emic insults (84). Therefore, the observed antiphospho-
lipid syndrome and endothelial damages that character-
ize COVID-19 patients would require further study on
the involvement of the complement cascade, as a possible
driver of COVID-19-associated coagulopathies (11).
Immunohistochemistry of minimal invasive autopsies from
coronavirus pneumonia patients displayed massive damage
in the alveolar structure, associated with robust infiltration
of inflammatory cells, mainly macrophages, monocytes,
and neutrophils (89). An extended series of 38 autopsies,
performed in the north of Italy, showed the inflammatory
infiltrate composed by alveolar macrophages and intersti-
tial lymphocytes, along with capillary congestion, necrosis
of pneumocytes, hyaline membrane, interstitial edema,
pneumocyte hyperplasia and reactive atypia, and signs of
platelet-fibrin thrombi in small arterial vessels (7a).
Transcriptome sequencing of the RNAs isolated from the
bronchoalveolar lavage fluid and peripheral blood mononu-
clear cells specimens of COVID-19 patients revealed distinct
host inflammatory cytokine profiles, highlighting the associa-
tion between COVID-19 pathogenesis and release of inflam-
matory chemokines, such as CCL2/MCP-1, CXCL10/IP-10,
CCL3/MIP-1A, and CCL4/MIP-1B. In addition, T cells
showed a significant association with the inflammatory sta-
tus in COVID-19 patients, and CD8 T cells, in particular,
tended to be an independent predictor of disease severity
and treatment efficacy (83), whereas chronic viral infection
can induce expression of negative cosignaling molecule pro-
grammed-death 1 (PD-1) and consequent T cell exhaustion
(63). Nevertheless, the observed patient’s lymphopenia cor-
related with induced activation of apoptosis and the p53
signaling pathway in lymphocytes (66). Within this sce-
nario, inflammation-driven hyperactivation of CD95-ex-
pressing (FasR) T lymphocytes can lead to their depletion
through a mutual suicide mechanism and therefore estab-
lish immunosuppression (21).
Comorbidities can heavily influence the immunological sce-
nario associated with COVID-19. It is known that cancer-
related inflammation alters the myelopoietic output, giving
rise to expansion of immature myeloid populations, with
anti-inflammatory and immunosuppressive functions (73).
Hence, the emerging skewing of monocytes/macrophages
towards an anti-inflammatory M2 activation state (74)
would potentially counteract the overwhelming classical in-
flammation imposed by viral infection, slowing down tissue
damage. In contrast, viral spreading might increase due to
ablation of specific immunity operated by the M2 polarized
and immunosuppressive innate immunity (24, 74).
While the net action of innate immune cells in COVID-19
remains to be clarified, a direct role of alveolar macro-
phages (AMs) was demonstrated in influenza virus infec-
tion, since their depletion increased susceptibility to virus
infection, independent of cytotoxic T cells (69). It appears
that selective targeting of innate immune components could
disclose therapeutic approaches. In this contest, iNAMPT
was recently identified as a critical modulator of immuno-
metabolism and mobilization of M2-polarized anti-inflam-
matory myeloid cells to the periphery in cancer bearers (80).
Furthermore, NAMPT metabolism participates in macro-
phage antiviral activity (18), hence highlighting its potential
relevance in the surveillance of homeostatic and immune
functions exercised by alveolar and interstitial macro-
phages. Preexisting antiviral response might suppress anti-
bacterial Th17 via IFN-induced IL-23 downregulation (12),
an effect that can be surpassed by the indiscriminate lym-
phopenia occurring along disease progression. Finally,
within the search for candidate vaccines against viral repli-
cation, the activation state of macrophages should be taken
into account, as anti-spike IgG can cause lung injury
during the early stages of infection, promoting recruit-
ment and accumulation of proinflammatory monocytes/
macrophages, an effect reduced by FcR blockade (50).
According to these premises, new evidence supports a
massive metabolic change in the serum of severe patients
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COVID-19, including macrophage, lipid, and amino acid
metabolism (71).
V. ACE2 AND INFLAMMATION
ACE2, strongly expressed in the heart and lungs, has been
identified as a functional SARS-CoV-2 receptor, through
binding and priming of the viral spike (S) proteins by the
serine protease TMPRSS2 (38). SARS-CoV-2 has also
evolved a unique S1/S2 protease cleavage site that is identi-
cal to a FURIN cleavable peptide present on human epithe-
lial sodium channel -subunit (ENaC-) and coexpressed
with ACE2 on the same cells of cardiovascular-renal-pul-
monary epithelia (41) and that is controlled by the renin-
angiotensin-aldosterone system. The issue of anti-proteases
has even broader application by targeting plasmin(ogen),
which is elevated in several disease conditions, all known to
worsen COVID-19 patients outcome including hyperten-
sion, diabetes, as well as cardiovascular and renal disease
(41). Importantly, sera from convalescent SARS patients
cross-neutralized SARS-2-S-driven entry (38), and incom-
ing evidences suggest that greater expression of ACE2 is
associated with most serious disease manifestations. Along
this line, soluble human ACE2 is an effective decoy receptor
engaging and subtracting the virus from the cellular recep-
tor, inhibiting early stages of SARS-CoV-2 infection (56). In
spite of its enzymatic nature, the net effect of COVID-19 on
ACE2 enzymatic activity is still unknown. This question is
of potential relevance considering that ACE2, a key car-
boxypeptidase of the renin-angiotensin system (RAS), effi-
ciently catalyzes the conversion of the inflammatory angio-
tensin II into the anti-inflammatory and antagonist peptide
angiotensin-(1–7) (4). As a whole, SARS-CoV-2 downregu-
lates ACE2, causing a decrease in the anti-inflammatory
component of angiotensin-(1–7), capable of improving ox-
ygenation and reducing lung injury and fibrosis (14). As a
consequence, accumulation of the proinflammatory angio-
tensin II occurs (40).
An emerging link exists between homeostatic pathways
(i.e., the NAMPT/NAD/SIRT1) and the RAS, the latter
involved in acute lung failure (40), cardiovascular function
(16), and SARS infections (44). The robustness of the
NAMPT/NAD/SIRT1 system is controlled by a balanced
nutritional supply of tryptophan, which together with vita-
min B3 provide the primary and rescue pathways for the
synthesis of NAD (5).
This metabolism-linked hypothesis appears to be supported
by genetic and pharmacological evidence, showing a pro-
tective role of ACE2 in acute lung injury (35, 40, 90), kid-
ney injury, and intestinal inflammation (34). Of relevance,
NAD availability depends on the de novo synthesis by the
kynurenine pathway from tryptophan, whose circulating
levels are strongly reduced during viral infection, resulting
in exacerbated inflammation and low CD4 T cell recovery
(20). Furthermore, ACE2 modulates tryptophan levels in
peripheral blood and, in a model of malnutrition, supple-
mentation of tryptophan and “nicotinamide/vitamin B3”
restored ACE2 activity and prevented exacerbated inflam-
mation (34).
As suggested by FIGURE 1, the hyperinflammatory syn-
drome associated with COVID-19 therefore requires an
in-depth analysis of the interactions between homeo-
static systems (i.e., NAMPT/NAD/SIRT1) and the acti-
vation states of inflammatory/immune populations. Its
relevance emerges clearly in the elderly where chronic
inflammation (inflammaging) contributes to NAMPT
downregulation in multiple tissues, hence establishing a
self-sustaining circuit which favors homeostatic fragility,
inflammatory/metabolic complications, and increased
susceptibility to infections (23).
VI. MUTUAL INTERFERENCE OF
THERAPEUTIC INTERVENTIONS IN
COVID-19 AND CANCER
As discussed, NAMPT/NAD metabolism is modulated both
in response to viral infections and tumor growth, suggesting
that the metabolic rewiring of the tumor may influence the
patient’s response to COVID disease. NAMPT inhibitors
have entered clinical trials for solid and nonsolid tumors,
due to their ability to lower NAD and ATP levels and, in
turn, interfere with malignant cell growth (25). Interest-
ingly, peripheral blood mononuclear cells from patients
with acute-type adult T cell leukemia (ATL) expressed sig-
nificantly higher levels of NAMPT protein, as compared
with healthy subjects, and a NAMPT inhibitor (FK866)
induced apoptosis of both ATL cells ex vivo and HTLV-1-
infected T cell lines in vitro, and markedly decreased the in
vivo growth of human ATL tumor xenografts (43). More-
over, in a model of GVHD, FK866 inhibited expansion of
alloreactive but not memory T cells, while promoting ex-
pansion of FoxP3 regulatory T cells and reducing the
tumor burden in mouse leukemia and graft-versus-leuke-
mia models (27). This may be particularly relevant since
recent reports identified the 2GPI-reactive T cells as a
driver of autoantibody production in anti-phospholipid
syndrome (66), providing a possible link with the anti-phos-
pholipid syndrome and endothelial damages that character-
ize COVID-19 patients (92). Activation of the early growth
response-1 (EGR-1), a member of early growth response
proteins family, is critical for the growth of cells and the
replication of numerous viruses, including coronavirus (6).
Of relevance, inhibition of NAD-dependent deacetylase
Sirt-1 leads to acetylation and prolonged expression of
EGR-1 in hyperglycemic conditions and establishes proin-
flammatory and prothrombotic responses in diabetic ath-
erosclerosis (82). These observations could underscore the
possible association between NAMPT/NAD metabolism,
comorbidities, and aggressive disease in COVID-19 pa-
tients.
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From a therapeutic perspective, the COVID-19-induced in-
crease of PD-1, along with the viral capacity to alter the
intracellular NAD levels of immune cells (43), would im-
prove anticancer efficacy of immune checkpoint inhibitors
(ICIs). Indeed, the reduced levels of NAD reduce mobiliza-
tion and differentiation of suppressive myeloid populations
in COVID-19 cancer patients, thereby removing an inhibi-
tory brake for immune stimulation through ICIs (58). How-
ever, this conclusion remains questionable because of the
accentuated lymphopenia observed in COVID-19 patients.
Another aspect shared by COVID-19 and ICI-treated can-
cer patients is the cytokine release syndrome (CRS), which
generates immune-related adverse effects (irAEs). Emerging
evidence indicates that ICI-induced irAEs arises through a
combination of pathways involving autoreactive T cells,
autoantibodies, and cytokines (64).
In contrast, the hyperinflammatory response in COVID-19
patients appears to be governed by innate immune re-
sponses, specifically the hematophagocytic lymphohistiocy-
tosis (HLH) mediated by macrophage activation syndrome
(MAS) (70), which is characterized by CRS, lymphopenia,
and multiorgan failure (70). According to this, a high num-
ber of activated macrophages are found in the lungs of
patients with COVID-19 (79). Importantly, in both types of
hyperinflammation (COVID-19 patients vs. cancer patients
undergoing ICIs), the elective treatments are steroids and
tocilizumab (1). Strategies blunting M1 polarization of
macrophages are expected to mitigate hyperinflammation.
Hydroxychloroquine, which is being now considered in
COVID-19 therapy, acts as both an oral hypoglycemic
agent (67) and an anti-inflammatory agent, by promoting
an M1 to M2 switch of macrophage polarization (72),
which eventually would support tumor progression (74).
The definition of myeloid cell plasticity in pathology has
been recently reformulated by the concept of innate im-
mune memory, comprising a set of epigenetic and metabolic
events promoting the functional reprogramming of the my-
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FIGURE 1. NAD metabolism in viral-induced inflammatory and metabolic dysregulation. NAD supply by food
sources (tryptophan, niacin, vitamin D) may compensate for COVID-19-induced hypovitaminosis, providing the
quantity needed for the deacetylating activity of SIRT1–7 targeting the transcription factors hypoxia inducible
factor (HIF)-1 and nuclear factor (NF)-B p65, thus promoting the resolution of inflammation. Estrogen-
induced expression of the vitamin D receptor supports consumption of vitamin D, strengthening NAD-depen-
dent events. Furthermore, NAD-mediated SIRT1–7 activity guides the production of the gasotransmitter
hydrogen sulfide (H2S), which favors vascular homeostasis and endothelial cell health. Aging and viral infections
weaken the NAMPT/NAD system favoring a state of fragility, typical of the comorbidities associated with
COVID-19 infection. The levels of androgens and estrogens act as protective and risk factors, respectively.
Cancer enhances NAMPT/NAD metabolism, promoting mobilization and differentiation of anti-inflammatory
myeloid-suppressor cells, as well as their alternative M2-polarization, which potentially buffers COVID-19-
related inflammation. While it remains to be established whether the anti-inflammatory action of angiotensin
converting enzyme 2 (ACE2) is directly promoted by NAMPT/NAD, it is known that ACE2 supports tryptophan
levels, which in turn feeds NAMPT/NAD metabolism. IL-6, interleukin-6.
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ary stimulation with pathogens, Toll-like receptor agonists,
and cytokines (59). Bacillus Calmette-Guérin (BCG) is a live
attenuated vaccine originally developed against tuberculo-
sis (52) and is now used as the gold-standard treatment for
non-muscle-invasive bladder cancer at high risk of recur-
rence or progression (62). Noteworthy, recent studies have
suggested that countries and regions that mandate BCG
vaccination for the population have a lower number of
infections and a reduced mortality from COVID-19 (33).
This response appears to be associated with epigenetic
changes in monocytes (i.e., innate immune immunity) (58)
that correlate with improved antiviral responses (2).
The prominent role of macrophages in tumor progression
and COVID-19 hyperinflammation suggests the possible
usefulness of macrophage-depleting drugs, such as clodro-
nate and zoledronic acid (74). The macrophage colony
stimulating factor (M-CSF) promotes differentiation of tis-
sue macrophages involved in tissue homeostasis (39) and
tumor progression (65). CSF-1 receptor (CSF-1R) inhibitor
promotes macrophage depletion and has been administered
orally, and also induced clinical regression in patients with
tenosynovial giant-cell tumors (77). Of relevance, a number
of chemotherapeutics display immunostimulatory proper-
ties and strongly influence myelopoiesis, revealing new
mechanisms with implications for immunotherapy (73). As
an example, trabectedin displays antitumor and macro-
phage-depleting properties (26).
VII. CONCLUSION
Patients with cancer seem to be particularly vulnerable to
COVID-19 because cancer, as a COVID-19 comorbidity,
can heavily influence the immunological scenario associ-
ated with viral infection. In fact, cancer-induced myelopoi-
etic alterations, accompanied by expansion of immunosup-
pressive immature myeloid populations, can limit antiviral
immunity (24, 29, 74). These alterations impact on the
virus-mediated breakout of physiological mechanisms of
robustness making it a dramatic event especially in elderly
male patients (20, 30, 42, 55, 91).
Both cancer and COVID-19 exploit distinct inflammatory
patterns expressed by macrophages, which promote disease
progression in their most severe forms. Converging evi-
dence indicates the primary involvement of macrophages in
inflammatory states associated with COVID-19 and cancer.
Of relevance, macrophages can express different functional
proteins in response to microenvironmental signals, a prop-
erty defined as functional plasticity. The extremes of their
functional flexibility are generally defined as classical M1-
and alternative M2-activation, which respectively identify a
cytotoxic inflammatory as opposed to an anti-inflamma-
tory, immunosuppressive activation state (74). The shift
between these antithetical activation states plays a distinct
role in infection and cancer (74), and new evidence also
supports its key role in hyperinflammation associated with
COVID-19 (53). Current literature data support a key role
for anti-inflammatory M2-polarized macrophage in can-
cer-related inflammation and tumor progression. In con-
trast, accumulating evidence indicates the MAS as the
source of M1-related cytokine storm, associated with
severe COVID-19 disease. These data suggest that distinct
macrophage activation states distinguish the two diseases,
while offering a common cellular target. In addition,
NAMPT/NAD metabolism is modulated both in response
to viral infections and tumor growth, suggesting that the
metabolic rewiring of the tumor may influence the patient’s
response to COVID-19 disease. Overall, understanding the
immunometabolic settings in tumors and viral infections
becomes a crucial new challenge to define pathogenetic
mechanisms in COVID-19 cancer patients.
To conclude, this review should be considered in a new
framework of cancer-specific data coming from cancer pa-
tient registries recently established. These longitudinal stud-
ies, together with the better understanding of the molecular
mechanisms of COVID-19 and cancer, support the in-
creased vulnerability of cancer patients, leaving the ques-
tion of whether the risk of death from COVID-19 changes
across different cancer types open. Additional data coming
from pan cancer registries and population-based cancer reg-
istries could address this question hopefully in the coming
months.
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